These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 22031689)

  • 1. [Cost-effectiveness analysis of active TDM in elderly patients treated with aminoglycosides].
    Leon-Djian CB; Bourguignon L; Späth HM; Maire P
    Therapie; 2011; 66(5):445-52. PubMed ID: 22031689
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Level of evidence for therapeutic drug monitoring of aminoglycosides].
    Venisse N; Boulamery A;
    Therapie; 2011; 66(1):39-44. PubMed ID: 21466776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, Poland--part II.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):491-5. PubMed ID: 16583990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Economic impact of standard antibiotic therapy combined with amikacin, in clinical unit, Lodz, poland--part I.
    Kusowska J
    Acta Pol Pharm; 2005; 62(6):485-90. PubMed ID: 16583989
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy, nephrotoxicity and ototoxicity of aminoglycosides, mathematically modelled for modelling-supported therapeutic drug monitoring.
    Croes S; Koop AH; van Gils SA; Neef C
    Eur J Pharm Sci; 2012 Jan; 45(1-2):90-100. PubMed ID: 22094306
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of goal-oriented and model-based clinical pharmacokinetic dosing of aminoglycosides on clinical outcome: a cost-effectiveness analysis.
    van Lent-Evers NA; Mathôt RA; Geus WP; van Hout BA; Vinks AA
    Ther Drug Monit; 1999 Feb; 21(1):63-73. PubMed ID: 10051056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of serum vancomycin concentration monitoring in patients with hematologic malignancies.
    Fernández de Gatta MD; Calvo MV; Hernández JM; Caballero D; San Miguel JF; Domínguez-Gil A
    Clin Pharmacol Ther; 1996 Sep; 60(3):332-40. PubMed ID: 8841156
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current use of aminoglycosides: indications, pharmacokinetics and monitoring for toxicity.
    Avent ML; Rogers BA; Cheng AC; Paterson DL
    Intern Med J; 2011 Jun; 41(6):441-9. PubMed ID: 21309997
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacist impact on care, length of stay, and cost in pediatric cystic fibrosis (CF) patients.
    Cies JJ; Varlotta L
    Pediatr Pulmonol; 2013 Dec; 48(12):1190-4. PubMed ID: 23281228
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aminoglycosides use in patients over 75 years old.
    Fraisse T; Gras Aygon C; Paccalin M; Vitrat V; De Wazieres B; Baudoux V; Lechiche C; Vicens A; Sotto A; Pagani L; Gaillat J; Forestier E; Gavazzi G
    Age Ageing; 2014 Sep; 43(5):676-81. PubMed ID: 24590569
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Economic impact of aminoglycoside toxicity and its prevention through therapeutic drug monitoring.
    Slaughter RL; Cappelletty DM
    Pharmacoeconomics; 1998 Oct; 14(4):385-94. PubMed ID: 10344906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A priori prediction of gentamicin peak concentrations: Use of a simple and practical tool].
    Mignaval F; Fontaine PA; Riché A; Nowak C; Cancel D; Lemaitre F
    Pathol Biol (Paris); 2011 Apr; 59(2):79-82. PubMed ID: 20822863
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cost considerations in therapeutic drug monitoring of aminoglycosides.
    Bertino JS; Rodvold KA; Destache CJ
    Clin Pharmacokinet; 1994 Jan; 26(1):71-81. PubMed ID: 8137600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Controversies in antimicrobial therapy: pitfalls in monitoring aminoglycoside therapy.
    Fant WK
    Am J Hosp Pharm; 1986 Mar; 43(3):641-6. PubMed ID: 3706319
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical experience with aminoglycosides in dialysis-dependent patients: risk factors for mortality and reassessment of current dosing practices.
    Heintz BH; Thompson GR; Dager WE
    Ann Pharmacother; 2011 Nov; 45(11):1338-45. PubMed ID: 22010003
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Individualized monitoring of the therapy with gentamycin using pharmacokinetic methods. Which method to choose?].
    Carvalho A; Fonseca C; Falcão F; Pereira TA; Freitas O; Parrinha A; Costa M; Rodrigues MJ; Ceia F; Luís AS
    Acta Med Port; 1996; 9(7-9):187-95. PubMed ID: 9005695
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Which partner for the betalactam agent in empirical combined therapy? II. Aminoglycoside].
    Mimoz O; Grollier G
    Ann Fr Anesth Reanim; 2004 Jun; 23(6):639-42. PubMed ID: 15234735
    [No Abstract]   [Full Text] [Related]  

  • 18. A utilization and cost-benefit analysis of an aminoglycoside kinetics monitoring service.
    Pinilla J; Shafran S; Conly J
    Clin Invest Med; 1992 Feb; 15(1):8-17. PubMed ID: 1572110
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Aminoglycosides in septic shock: an overview, with specific consideration given to their nephrotoxic risk.
    Boyer A; Gruson D; Bouchet S; Clouzeau B; Hoang-Nam B; Vargas F; Gilles H; Molimard M; Rogues AM; Moore N
    Drug Saf; 2013 Apr; 36(4):217-30. PubMed ID: 23508544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aminoglycosides for life-threatening infections: a plea for an individualized approach using intensive therapeutic drug monitoring.
    De Waele JJ; De Neve N
    Minerva Anestesiol; 2014 Oct; 80(10):1135-42. PubMed ID: 24326971
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.